Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Preoperative assessment of colorectal cancer requires a multimodal approach including clinical, radiographic, biochemical and colonoscopic assessment with histologic review of biopsies that provides valuable information regarding tumor grading and other significant prognostic factors that aid in determination of the appropriate treatment. The association between Musashi-2 expression and clinicopathological features and its prognostic significance in CRC patients is still controversial. Our study is designed to investigate the expression and prognostic significance of MSI2 and CD163+Tumor associated macrophages in colorectal cancer patients.
Methods: Prospective longitudinal study was designed including 114 CRC cases from Tropical Medicine Department and Oncology Center, Mansoura University Hospitals, during the period from July 2021 to October 2024, all cases were diagnosed by colonoscopy then underwent radical surgery with biopsies which were examined by IHC staining for MSI2 and CD163+TAM using tissue microarray technique trying to find out their correlation with clinicopathological parameters and patients prognosis.
Results: Among 114 CRC cases, high MSI2 expression was detected in 49 (43%). MSI2 expression was significantly related to grade of differentiation (P = 0.001*), depth of invasion (P = 0.001*), lymph node metastasis (P = 0.001*), TNM stage (P = 0.001*) and hepatic metastasis (P = 0.009*). Multivariate analysis spotted MSI2 expression as a predictor for Overall survival in CRC (P = 0.015*) and disease free survival (P = 0.008*). CD163+TAM showed a significant correlation to grade of differentiation (P = 0.001*), depth of invasion (P = 0.05*), lymph node metastasis (P = 0.001*), TNM stage (P = 0.001*), and hepatic metastasis (P = 0.007*). Multivariate analysis spotted CD163+TAM expression as a predictor for OS in CRC (P = 0.037*) and DFS (P = 0.003*).
Conclusion: MSI2 and CD163+TAM are independent prognostic factors for the overall survival and disease free survival and can predict poor prognosis in CRC patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227984 | PMC |
| http://dx.doi.org/10.31557/APJCP.2025.26.4.1429 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Accounting for endoscopic screening in colorectal cancer risk models.
Cancer Epidemiol Biomarkers Prev
September 2025
Brigham and Women's Hospital, Boston, MA, United States.
Background: Colorectal cancer (CRC) risk models routinely adjust for endoscopic screening because of a) possible confounding with other risk factors and b) possible alteration of natural history of the disease due to adenoma detection and removal.
Methods: In this study, we defined a subject as screen-covered (SC) if a colonoscopy was performed in the past 10 years, and not screen-covered (NSC) otherwise. We created CRC risk models separately for SC and NSC subjects (HRSC, HRNSC) and then obtained a screening-coverage adjusted HR estimate (HRfull) based on a weighted average of ln(HRSC) and ln(HRNSC) with weight equal to the proportion of SC person-time in the NHS population.
Stanford Type A Aortic Dissection During Adjuvant Capecitabine Chemotherapy for Colorectal Cancer.
JACC Case Rep
September 2025
Department of Cardiovascular Surgery, Nagoya Heart Center, Nagoya, Japan.
Background: Capecitabine, an oral prodrug of 5-fluorouracil, is widely used for gastrointestinal malignancies. While its coronary toxicity is well documented, large-vessel complications such as aortic dissection are rarely reported.
Case Summary: We present a 65-year-old man with colorectal cancer who developed Stanford type A aortic dissection 3 days after initiating adjuvant capecitabine therapy.
Challenges of decision-making after treatment with immunotherapy in metastatic deficient DNA mismatch repair/microsatellite unstable colorectal cancer.
Br J Surg
September 2025
Department of Digestive Surgery, CARPEM Comprehensive Cancer Centre, Georges-Pompidou European Hospital, AP-HP, Université Paris-Cité, Paris, France.
The effectiveness of three months EGFR-CTH therapy in palliative colorectal cancer.
Rep Pract Oncol Radiother
August 2025
Cardiac Surgery and Transplantology Department, Poznan University of Medical Sciences, Poznan, Poland.
Background: The rising burden of colorectal cancer with a high prevalence of advanced stages of new-onset is reported worldwide. While applied, chemotherapy can extend patients' survival, and proper tailoring is paramount. Based on computed tomography results, the study aimed to point out potential prognostic factors of complete or partial response to the initial three months of chemotherapy in palliative colorectal (CRC) cancer.
View Article and Find Full Text PDFNatural product Erianin: mitigating FOLFOX toxicity and enhancing against colorectal cancer.
Front Chem
August 2025
Guangzhou Key Laboratory of Formula-Pattern Research Center, School of Traditional Chinese Medicine, The Fifth Affiliated Hospital of Jinan University (Heyuan Shenhe People's Hospital), Jinan University, Guangzhou, China.
Introduction: Colorectal cancer (CRC) is a prevalent malignant tumor of the digestive tract. The FOLFOX regimen (oxaliplatin + calcium folinate + 5-fluorouracil) serves as the primary treatment for advanced CRC clinically, yet its application is significantly limited by substantial toxic side effects. Erianin, a natural compound from Chinese medicine Lindl, demonstrates significant potential in both tumor growth inhibition and chemotherapy toxicity reduction.
View Article and Find Full Text PDF